Literature DB >> 30833430

Assessment of the Potential for Inducing Resistance in Multidrug-Resistant Organisms from Exposure to Minocycline, Rifampin, and Chlorhexidine Used To Treat Intravascular Devices.

Joel Rosenblatt1, Nylev Vargas-Cruz2, Ruth A Reitzel2, Issam I Raad2.   

Abstract

To assess the potential for the induction of antimicrobial resistance following repeated subinhibitory exposures to the combination minocycline (MIN), rifampin (RIF), and chlorhexidine (CHX), a total of 29 clinical microbial pathogenic isolates were repeatedly exposed to subinhibitory concentrations of MIN, RIF, and CHX for 20 passages. MICs of the MIN, RIF, and CHX combination were assessed at each passage to evaluate the potential for resistance to have been induced. The combination of MIN, RIF, and CHX showed significant antimicrobial efficacy and synergy against organisms resistant to all 3 individual components (MIC of ≥16 μg/ml for MIN or MIC of ≥4 μg/ml for RIF or CHX). Among the organisms originally resistant to 2 or more individual components and the organisms originally susceptible to 2 or more individual components, there was no evidence that organisms became resistant following 20 repeated subinhibitory exposure cycles to the triple combination. The risk of resistance developing to the triple combination is extremely low because microbes are inhibited or killed before resistance can simultaneously emerge to all three agents. Surveillance studies monitoring the development of resistance should be conducted in a clinical setting.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  chlorhexidine; intravascular devices; intravascular infections; minocycline; multidrug-resistant organisms; rifampin

Mesh:

Substances:

Year:  2019        PMID: 30833430      PMCID: PMC6496037          DOI: 10.1128/AAC.00040-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Functional, biophysical, and structural bases for antibacterial activity of tigecycline.

Authors:  Matthew W Olson; Alexey Ruzin; Eric Feyfant; Thomas S Rush; John O'Connell; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Occurrence and new mutations involved in rifampicin-resistant Propionibacterium acnes strains isolated from biofilm or device-related infections.

Authors:  Ulrika Furustrand Tafin; Guillaume Ghislain Aubin; Gerhard Eich; Andrej Trampuz; Stéphane Corvec
Journal:  Anaerobe       Date:  2015-05-18       Impact factor: 3.331

3.  Preventing CLABSIs among pediatric hematology/oncology inpatients: national collaborative results.

Authors:  David G Bundy; Aditya H Gaur; Amy L Billett; Bing He; Elizabeth A Colantuoni; Marlene R Miller
Journal:  Pediatrics       Date:  2014-11-17       Impact factor: 7.124

4.  Clinical effectiveness and risk of emerging resistance associated with prolonged use of antibiotic-impregnated catheters: more than 0.5 million catheter days and 7 years of clinical experience.

Authors:  Elizabeth R Ramos; Ruth Reitzel; Ying Jiang; Ray Y Hachem; Ann Marie Chaftari; Roy F Chemaly; Brenda Hackett; S Egbert Pravinkumar; Joseph Nates; Jeffrey J Tarrand; Issam I Raad
Journal:  Crit Care Med       Date:  2011-02       Impact factor: 7.598

5.  Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa.

Authors:  T Köhler; M Michea-Hamzehpour; P Plesiat; A L Kahr; J C Pechere
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  Rifampin: mechanisms of action and resistance.

Authors:  W Wehrli
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

7.  Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: a prospective, randomized study.

Authors:  Ioannis Chatzinikolaou; Kevin Finkel; Hend Hanna; Maha Boktour; John Foringer; Tam Ho; Issam Raad
Journal:  Am J Med       Date:  2003-10-01       Impact factor: 4.965

8.  Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial.

Authors:  Hend Hanna; Robert Benjamin; Ioannis Chatzinikolaou; Badie Alakech; Deborah Richardson; Paul Mansfield; Tanya Dvorak; Mark F Munsell; Rabih Darouiche; Hagop Kantarjian; Issam Raad
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

9.  Fosfomycin and rifampin disk diffusion tests for detection of Escherichia coli mutator strains.

Authors:  Juan-Carlos Galán; Marta Tato; María-Rosario Baquero; Carmen Turrientes; Fernando Baquero; José-Luis Martinez
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

10.  Prevention of biofilm colonization by Gram-negative bacteria on minocycline-rifampin-impregnated catheters sequentially coated with chlorhexidine.

Authors:  Mohamed A Jamal; Joel S Rosenblatt; Ray Y Hachem; Jiang Ying; Egbert Pravinkumar; Joseph L Nates; Anne-Marie P Chaftari; Issam I Raad
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

View more
  1 in total

Review 1.  The potential for developing new antimicrobial resistance from the use of medical devices containing chlorhexidine, minocycline, rifampicin and their combinations: a systematic review.

Authors:  Ruth A Reitzel; Joel Rosenblatt; Bahgat Z Gerges; Andrew Jarjour; Ana Fernández-Cruz; Issam I Raad
Journal:  JAC Antimicrob Resist       Date:  2020-02-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.